Fulgent Genetics, Inc.
$506.09M- Market cap
- $555.81M
- Debt
- +$476.00K
- Cash
- −$50.19M
Capital structure 100% equity / 0% debt · EV / Revenue 1.57x
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
FY 2025 ·
Decision snapshot: FLGT stock price vs ITRI: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ITRI's multiple
Needs ITRI P/S.
Implied fair value · at FLGT's multiple
Metric by metric
Price unavailable
Where each company leads, and how wide the gap is.
Growth edge
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
Market cap plus debt, less cash.
Capital structure 100% equity / 0% debt · EV / Revenue 1.57x
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
FULGENT GENETICS, INC. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
Itron, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Debt / equity
Total debt against shareholders' equity
0.00x
1.00x
Net debt / EBITDA
Leverage against operating earnings
1.15x
1.67x
Cash and equivalents
Liquid reserves on the balance sheet
$50.19M
$1.02B
Total debt
Interest-bearing obligations outstanding
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
NEOGENOMICS INC
FLGT vs NEO
Natera, Inc.
FLGT vs NTRA
Guardant Health, Inc.
FLGT vs GH
EXACT SCIENCES CORP
FLGT vs EXAS
OPKO HEALTH, INC.
FLGT vs OPK
EMERSON ELECTRIC CO
FLGT vs EMR
Eaton Corp plc
FLGT vs ETN
BADGER METER INC
FLGT vs BMI
CISCO SYSTEMS, INC.
FLGT vs CSCO
Leidos Holdings, Inc.
FLGT vs LDOS
VERISIGN INC/CA
FLGT vs VRSN
$476.00K
$1.72B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.